This clinical trial is testing a new treatment for ovarian cancer. The trial is in phase 2, which means it is checking how well the treatment works and its safety. The treatment involves a new drug called ADP-A2M4CD8, used alone or with another drug called nivolumab. Nivolumab is a type of medicine that helps the immune system fight cancer cells.

Participants must be HLA-A2+ and have MAGE-A4 positive ovarian cancer. HLA-A2 is a specific protein on cells that helps the immune system recognize them. MAGE-A4 is a protein found in some cancer cells. Participants need to be between 18 and 75 years old and have certain health conditions to join. The study will have regular check-ups and tests to monitor the effects of the treatment.

Consider these key points:

• The study requires commitment to regular hospital visits for treatment and check-ups.
• Participants must not have certain other illnesses or be pregnant.
• There might be risks, like side effects from the drugs.